HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later
- PMID: 21412422
- PMCID: PMC3055880
- DOI: 10.1371/journal.pone.0017569
HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later
Abstract
Aims/hypothesis: HLA genes, islet autoantibodies and residual C-peptide were studied to determine the independent association of each exposure with diabetic retinopathy (DR), 15 years after the clinical onset of type 1 diabetes in 15-34 year old individuals.
Methods: The cohort was identified in 1992 and 1993 by the Diabetes Incidence Study in Sweden (DISS), which investigates incident cases of diabetes for patients between 15 and 34 years of age. Blood samples at diagnosis were analyzed to determine HLA genotype, islet autoantibodies and serum C-peptide. In 2009, fundus photographs were obtained from patient records. Study measures were supplemented with data from the Swedish National Diabetes Registry.
Results: The prevalence of DR was 60.2% (148/246). Autoantibodies against the 65 kD isoform of glutamate decarboxylase (GADA) at the onset of clinical diabetes increased the risk of DR 15 years later, relative risk 1.12 for each 100 WHO units/ml, [95% CI 1.02 to 1.23]. This equates to risk estimates of 1.27, [95% CI 1.04 to 1.62] and 1.43, [95% CI 1.06 to 1.94] for participants in the highest 25(th) (GADA>233 WHO units/ml) and 5(th) percentile (GADA>319 WHO units/ml) of GADA, respectively. These were adjusted for duration of diabetes, HbA(1c), treated hypertension, sex, age at diagnosis, HLA and C-peptide. Islet cell autoantibodies, insulinoma-antigen 2 autoantibodies, residual C-peptide and the type 1 diabetes associated haplotypes DQ2, DQ8 and DQ6 were not associated with DR.
Conclusions: Increased levels of GADA at the onset of type 1 diabetes were associated with DR 15 years later. These results, if confirmed, could provide additional insights into the pathogenesis of the most common microvascular complication of diabetes and lead to better risk stratification for both patient screenings and DR treatment trials.
Conflict of interest statement
Figures
Similar articles
-
Tissue transglutaminase autoantibodies in children with newly diagnosed type 1 diabetes are related to human leukocyte antigen but not to islet autoantibodies: A Swedish nationwide prospective population-based cohort study.Autoimmunity. 2018 Aug;51(5):221-227. doi: 10.1080/08916934.2018.1494160. Epub 2018 Nov 16. Autoimmunity. 2018. PMID: 30444426
-
Analysis of pathogenesis of juvenile new-onset diabetes.J Diabetes. 2011 Jun;3(2):132-7. doi: 10.1111/j.1753-0407.2010.00105.x. J Diabetes. 2011. PMID: 21138544 Free PMC article.
-
[Prevalence and predictive value of GAD65 autoantibodies and their correlation with HLA DR-DQ genotypes in children with type-1 diabetes].Orv Hetil. 2003 Feb 23;144(8):355-60. Orv Hetil. 2003. PMID: 12666382 Hungarian.
-
Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes.Am J Med Genet. 2002 May 30;115(1):48-54. doi: 10.1002/ajmg.10343. Am J Med Genet. 2002. PMID: 12116176 Review.
-
Persistence of islet autoantibodies after diagnosis in type 1 diabetes.Diabet Med. 2021 Dec;38(12):e14712. doi: 10.1111/dme.14712. Epub 2021 Oct 22. Diabet Med. 2021. PMID: 34614253 Review.
Cited by
-
From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes.Curr Diab Rep. 2025 Jun 24;25(1):38. doi: 10.1007/s11892-025-01595-1. Curr Diab Rep. 2025. PMID: 40553206 Free PMC article. Review.
-
HLA class I and II alleles are associated with microvascular complications of type 1 diabetes.Hum Immunol. 2013 May;74(5):538-44. doi: 10.1016/j.humimm.2013.01.013. Epub 2013 Jan 29. Hum Immunol. 2013. PMID: 23376458 Free PMC article.
-
The association of islet autoantibodies with the neural retinal thickness and microcirculation in type 1 diabetes mellitus with no clinical evidence of diabetic retinopathy.Acta Diabetol. 2024 Jul;61(7):897-907. doi: 10.1007/s00592-024-02255-8. Epub 2024 Mar 26. Acta Diabetol. 2024. PMID: 38530415
-
Depleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere?Diabetes. 2013 Nov;62(11):3669-70. doi: 10.2337/db13-1207. Diabetes. 2013. PMID: 24158996 Free PMC article. No abstract available.
-
Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment.Ophthalmol Sci. 2024 Feb 17;4(4):100494. doi: 10.1016/j.xops.2024.100494. eCollection 2024 Jul-Aug. Ophthalmol Sci. 2024. PMID: 38694495 Free PMC article. Review.
References
-
- Diabetes. 2008. Fact sheet Number 312: World Health Organization.
-
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–986. - PubMed
-
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853. - PubMed
-
- Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007;30:1995–1997. - PubMed
-
- Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275–1279. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous